People

Douglas Kyle Hogarth, MD

  • Professor of Medicine
  • Research and Scholarly Interests: alpha 1 Antitrypsin Deficiency, bronchial thermoplasty, Bronchoscopy, Emphysema, Lung Cancer, lung mass, lung nodule, Lung Volume Reduction, robotic bronchoscopy, severe asthma
  • Websites: Research Network Profile
  • Contact: dhogarth@uchicago.edu

D. Kyle Hogarth, MD, FCCP, is a Professor of Medicine in the Section of Pulmonary and Critical Care Medicine at The University of Chicago. He is the Director of Bronchoscopy and is heavily involved in the field of advanced bronchoscopy and interventional pulmonary with numerous publications.

Dr. Hogarth received his medical degree at Case Western Reserve University School of Medicine in Cleveland, Ohio. He then completed a residency in Internal Medicine and a fellowship in Pulmonary and Critical Care at The University of Chicago. He has been published in the New England Journal of Medicine, Chest, ERJ and many other journals. He serves on the editorial board of CHEST, where he is the section editor for the podcast section. He has won numerous clinical awards and teaching awards from his University. He is a founding member and the past President of the Society for Advanced Bronchoscopy.

University of Chicago
Chicago, IL
- Pulmonary and Critical Care
2004

University of Chicago
Chicago, IL
- internal Medicine
2001

Case Western Reserve
Cleveland, OH
MD - Medicine
1998

Miami University
Oxford, OH
BA - Chemistry, Biology, and Microbiology (triple major)
1994

NAVIGATE 24-Month Results: Electromagnetic navigation bronchoscopy for pulmonary lesions at 37 centers in Europe and the United States.
Folch EE, Bowling MR, Pritchett MA, Murgu SD, Nead MA, Flandes J, Krimsky WS, Mahajan AK, LeMense GP, Murillo BA, Bansal S, Lau K, Gildea TR, Christensen M, Arenberg DA, Singh J, Bhadra K, Hogarth DK, Towe CW, Lamprecht B, Bezzi M, Mattingley JS, Hood KL, Lin H, Wolvers JJ, Khandhar SJ. NAVIGATE 24-Month Results: Electromagnetic navigation bronchoscopy for pulmonary lesions at 37 centers in Europe and the United States. J Thorac Oncol. 2021 Dec 29.
PMID: 34973418

Bronchial Thermoplasty in Severe Asthmatics At 5 Years: The PAS2 Study.
Chupp G, Kline JN, Khatri SB, McEvoy C, Silvestri GA, Shifren A, Castro M, Bansal S, McClelland M, Dransfield M, Trevor J, Kahlstrom N, Simoff M, Wahidi MM, Lamb CR, Ferguson JS, Haas A, Hogarth DK, Tejedor R, Toth J, Hey J, Majid A, LaCamera P, FitzGerald JM, Enfield K, Grubb GM, McMullen EA, Olson JL, Laviolette M. Bronchial Thermoplasty in Severe Asthmatics At 5 Years: The PAS2 Study. Chest. 2021 Nov 10.
PMID: 34774528

Asthma-associated genetic variants induce IL33 differential expression through an enhancer-blocking regulatory region.
Aneas I, Decker DC, Howard CL, Sobreira DR, Sakabe NJ, Blaine KM, Stein MM, Hrusch CL, Montefiori LE, Tena J, Magnaye KM, Clay SM, Gern JE, Jackson DJ, Altman MC, Naureckas ET, Hogarth DK, White SR, Gomez-Skarmeta JL, Schoetler N, Ober C, Sperling AI, Nóbrega MA. Asthma-associated genetic variants induce IL33 differential expression through an enhancer-blocking regulatory region. Nat Commun. 2021 10 21; 12(1):6115.
PMID: 34675193

A-to-I editing of miR-200b-3p in airway cells is associated with moderate-to-severe asthma.
Magnaye KM, Naughton KA, Huffman J, Hogarth DK, Naureckas ET, White SR, Ober C. A-to-I editing of miR-200b-3p in airway cells is associated with moderate-to-severe asthma. Eur Respir J. 2021 07; 58(1).
PMID: 33446603

Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models.
Martinez-Zayas G, Almeida FA, Yarmus L, Steinfort D, Lazarus DR, Simoff MJ, Saettele T, Murgu S, Dammad T, Duong DK, Mudambi L, Filner JJ, Molina S, Aravena C, Thiboutot J, Bonney A, Rueda AM, Debiane LG, Hogarth DK, Bedi H, Deffebach M, Sagar AS, Cicenia J, Yu DH, Cohen A, Frye L, Grosu HB, Gildea T, Feller-Kopman D, Casal RF, Machuzak M, Arain MH, Sethi S, Eapen GA, Lam L, Jimenez CA, Ribeiro M, Noor LZ, Mehta A, Song J, Choi H, Ma J, Li L, Ost DE. Predicting Lymph Node Metastasis in Non-small Cell Lung Cancer: Prospective External and Temporal Validation of the HAL and HOMER Models. Chest. 2021 09; 160(3):1108-1120.
PMID: 33932466

Augmented Fluoroscopy: A New and Novel Navigation Platform for Peripheral Bronchoscopy.
Cicenia J, Bhadra K, Sethi S, Nader DA, Whitten P, Hogarth DK. Augmented Fluoroscopy: A New and Novel Navigation Platform for Peripheral Bronchoscopy. J Bronchology Interv Pulmonol. 2021 Apr 01; 28(2):116-123.
PMID: 33105419

What should we realistically expect from robotic bronchoscopy in the near future?
Ho E, Agrawal A, Hogarth DK, Murgu S. What should we realistically expect from robotic bronchoscopy in the near future? J Thorac Dis. 2021 Jan; 13(1):405-408.
PMID: 33570511

Improving diagnostic yield of navigational bronchoscopy for peripheral pulmonary lesions: a review of advancing technology.
Wagh A, Ho E, Murgu S, Hogarth DK. Improving diagnostic yield of navigational bronchoscopy for peripheral pulmonary lesions: a review of advancing technology. J Thorac Dis. 2020 Dec; 12(12):7683-7690.
PMID: 33447461

Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.
PMID: 33234578

Augmented Fluoroscopy: A New and Novel Navigation Platform for Peripheral Bronchoscopy.
Cicenia J, Bhadra K, Sethi S, Nader DA, Whitten P, Hogarth DK. Augmented Fluoroscopy: A New and Novel Navigation Platform for Peripheral Bronchoscopy. J Bronchology Interv Pulmonol. 2020 Oct 23.
PMID: 33105419

View All Publications